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Background: Goal attainment of guideline-recommended low-density lipoprotein cholesterol (LDL-C) is suboptimal.
Little is known about how patient factors influence physicians’ treatment decision-making in hypercholesterolemia.
We examined physicians’ treatment recommendations in high-risk patients whose LDL-C remained uncontrolled
despite statin monotherapy.
Methods: Physicians completed a questionnaire prior to randomization into period I of a two-period randomized
controlled trial evaluating LDL-C goal attainment in patients whose LDL-C remained ≥100 mg/dL after 5 weeks’
treatment with atorvastatin 10 mg/day (NCT01154036). Physicians’ treatment recommendations were surveyed
for two hypothetical and one real scenario: (1) LDL-C presumed near goal (between 100–105 mg/dL), (2) LDL-C
presumed far from goal (~120 mg/dL), and (3) observed baseline LDL-C of enrolled patients. Prognostic factors
considered during decision-making were identified by regression analysis. Observed lipid outcomes at the end of
period I (following 6 weeks’ treatment with ezetimibe 10 mg plus atorvastatin 10 mg, atorvastatin 20 mg, or
rosuvastatin 10 mg) were compared with estimated LDL-C outcomes for physicians’ treatment recommendations
after 6 weeks (based on individual patients’ pre-randomization LDL-C and expected incremental change).
Results: Questionnaires were completed for 1,534 patients. No change in therapy, or double atorvastatin dose,
were frequently recommended, even when LDL-C was far from goal (6.5% and 52.2% of patients, respectively).
Double atorvastatin dose was commonly recommended in all scenarios (43–52% of patients). More intensive
LDL-C-lowering regimens were recommended infrequently e.g. double atorvastatin dose and add ezetimibe
only <12% in all scenarios. Overall, cardiovascular risk factors and desire to achieve a more aggressive LDL-C goal
were prominent factors in decision-making for treatment. Comparison of observed and estimated LDL-C levels
showed that physicians tended to overestimate the effectiveness of their recommendations.
Conclusions: This study provides insight into physicians’ perspectives on clinical management of hypercholesterolemia
and highlights a gap in knowledge translation from guidelines to clinical practice. The need for lower LDL-C and
cardiovascular risk were key drivers in clinical decision-making, but physicians’ treatment choices were more
conservative than guideline recommendations, potentially resulting in poorer LDL-C reduction. When compared
with actual outcomes, projected LDL-C control was better if physicians used more comprehensive strategies rather
than simply doubling the statin dose.
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Reducing low-density lipoprotein cholesterol (LDL-C)
levels with statin therapy is associated with clear benefit in
reducing cardiovascular risk [1]. For years, both European
and US dyslipidemia guidelines advocated a treat-to-target
approach for LDL-C reduction to <100 mg/dL [2,3]. Since
the development of this study, American Heart Associ-
ation/American College of Cardiology guidelines have ad-
vocated a shift away from LDL-C treatment targets per se
to focus on identifying patients most likely to benefit
from high-intensity (LDL-C reduction ≥50%) or moderate-
intensity (LDL-C reduction 30 - <50%) statin therapy [4].
International guidelines, however, continue to advocate a
treat-to-target approach, albeit with a more stringent
LDL-C target for very high cardiovascular risk patients
of <70 mg/dL or a 50% reduction from baseline, com-
pared with an LDL-C target of <100 mg/dL for high car-
diovascular risk patients [5,6].
Many patients at high cardiovascular risk receiving
statin monotherapy experience sub-optimal LDL-C-
lowering with persistent residual risk [7-9]. Retrospective
analysis of medical records for >27,400 US patients with
very high cardiovascular risk (e.g., coronary heart disease
or atherosclerotic vascular disease) with prescriptions
for atorvastatin monotherapy showed that >65% of patients
had LDL-C levels >70 mg/dL and, of these, 30–40% had
LDL-C ≥20 mg/dL in excess of this level regardless of dose
[7]. Where LDL-C-lowering remains sub-optimal on statin
monotherapy, guidelines generally recommend using the
maximum tolerated statin dose in high-risk individuals
[4,5] or introducing combination therapy with another
lipid-lowering agent [5,10-12].
In clinical practice, physicians may/should use evidence-
based guidelines to implement an individualized sequential
treatment approach to lipid management, particularly for
relatively challenging high-risk patients who require more
intensive LDL-C reduction. Nevertheless, failure to achieve
therapeutic LDL-C targets persists for various reasons,
including non-adherence, intolerance and cost factors
[13-16]. For high-risk patients, including those who may
be poor responders and/or intolerant to treatment with
higher statin doses, baseline levels can greatly exceed target
values making it difficult to achieve LDL-C goals. In
addition, achieving target LDL-C may require several steps,
such as dose uptitration, or combination therapy; thus,
compliance and cost factors can be an issue. Physicians’
knowledge, attitudes, and beliefs also play a major role in
the translation of guideline-based evidence to the treat-
ment choices they make in clinical practice [17-19]. Specif-
ically, organizational structures, time constraints, perceived
lack of usefulness of guidelines, and knowledge gaps com-
monly preclude wider implementation of best-practice rec-
ommendations [20]. Furthermore, with physician-patient
partnerships increasingly promoted in healthcare decision-making, physicians (particularly in general practice) often
adopt a pragmatic and flexible approach to guideline im-
plementation in order to preserve relationships with their
patients [12,21,22].
To date, there has been little study of patient charac-
teristics that influence physicians’ treatment decisions.
We therefore conducted a questionnaire-based survey of
physicians participating in a randomized controlled trial
(RCT) to better understand physician attitudes/beliefs
and patient characteristics that influence clinical decision-
making for specific treatments in hypercholesterolemia.
The primary results of the RCT, which assessed LDL-C
goal attainment rates in high-risk patients with hyperchol-
esterolemia and elevated LDL-C on atorvastatin mono-
therapy when changed to more potent LDL-C-lowering
therapies (i.e., uptitration, ezetimibe add-on, or switch
to a more potent statin), have been published previously
(NCT01154036) [23].
Here we report the findings of the questionnaire-based
survey, which assessed physicians’ treatment recommen-
dations and prognostic factors involved in decision-
making for two hypothetical and one real scenario: (1)
LDL-C presumed near goal (between 100–105 mg/dL),
(2) LDL-C presumed far from goal (~120 mg/dL), and
(3) observed baseline LDL-C. The survey was conducted
just prior to randomization of each patient into the RCT,
thus providing a unique opportunity to compare esti-
mated outcomes based on treatment choices made in a
real-life clinical setting with those obtained under strict
protocol guidance during an actual RCT.
Results
Physician and patient characteristics
Physicians at 296 sites in 29 countries randomized 1,547
patients to receive treatment with ezetimibe 10 mg plus
atorvastatin 10 mg, atorvastatin 20 mg, or rosuvastatin
10 mg daily for 6 weeks during period I of a phase III,
two-period, multicenter, double-blind RCT [23]; 1,460 of
these patients completed period I.
Physicians completed the pragmatic use questionnaire
for a total of 1,534 male and female patients at high car-
diovascular risk; the majority (67.2%) were aged <65 years
and approximately 50% had prior history of cardiovascular
disease (CVD) (Table 1). In total, 57.7% of questionnaires
were completed by specialist physicians and 42.3% by pri-
mary care physicians (Table 2).
Randomized controlled trial
The observed mean (standard deviation) baseline LDL-C
(mg/dL) of patients randomized into period I of the RCT
was: 121 (18) for ezetimibe 10 mg plus atorvastatin 10 mg,
120 (17) for atorvastatin 20 mg, and 121 (18) for rosuvas-
tatin 10 mg. After 6 weeks’ double-blind treatment, at the
end of period I, the percent change from baseline in LDL-
Table 1 Patient characteristics (visit 3: one week prior to
pre-randomization)
n = 1,534 patients
Age, n (%)
<65 years 1031 (67.2)
≥65 years 503 (32.8)
Male, n (%) 728 (47.5)
Prior history of CVD, n (%) 774 (50.5)
LDL-C (mg/dL), mean (SD) 121 (18)
EZE 10 mg + ATV 10 mg 121 (18)
ATV 20 mg 120 (17)
RSV 10 mg 121 (18)
LDL-C (mg/dL), n (%)
<85 11 (0.7)
85–100 133 (8.7)
100–130 956 (62.3)
130–160 411 (26.8)
≥160 23 (1.5)
ATV, atorvastatin; EZE, ezetimibe; CVD, cardiovascular disease; LDL-C, low-density
lipoprotein cholesterol; RSV, rosuvastatin.
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treatment groups.
Recommended treatment choice
Among the treatment choices, the four most common
recommendations for all three LDL-C scenarios sur-
veyed were: (a) no change in therapy, (b) double the
atorvastatin dose, (c) add ezetimibe, and (d) double the
atorvastatin dose and add ezetimibe, albeit with variabil-
ity across the three scenarios (Table 3). Notable data re-
lating to the impact of a fifth recommendation – switch
to rosuvastatin – is also provided in Table 3. Higher mean
baseline LDL-C values tended to be associated with rec-
ommendations for more intensive therapy. No change in
therapy, clearly the most conservative approach, was asso-
ciated with the lowest mean LDL-C value. Doubling the
atorvastatin dose and adding ezetimibe was associated
with the highest mean LDL-C level. Mean baseline LDL-CTable 2 Physician characteristics
n = 1,534 patients
Type of physician, n (%)
Primary care physician 649 (42.3)
Specialist 885 (57.7)
Years of practicing medicine
<5 152 (9.9)
5–9 201 (13.1)
10–19 367 (23.9)
≥20 814 (53.1)levels were similar in patients recommended to switch to
rosuvastatin or add ezetimibe.
Doubling the atorvastatin dose was the most common
treatment recommendation across all scenarios, recom-
mended for 42.8–52.2% of patients, although physicians
recommended no change in therapy in a similar propor-
tion of patients when LDL-C was presumed close to goal
(42.3%). Interestingly, no change in therapy was recom-
mended by physicians in approximately 18% of patients,
even when they were aware of the patients’ observed base-
line LDL-C level. Physicians recommended more intensive
or modified LDL-C-lowering regimens when LDL-C was
presumed far from versus near to goal. Interestingly, no
change in therapy was still recommended in 6.5% of pa-
tients when LDL-C was presumed far from goal. In
general, treatment recommendations by physicians were
conservative: the combined treatment by adding ezetimibe
or doubling the atorvastatin dose and adding ezetimibe
were recommended infrequently (in <11.6% – 15.6% of
patients) in all three scenarios, while switch to rosuvasta-
tin was recommended for fewer than 4.3% of patients
when LDL-C was presumed far from goal.
Factors affecting physicians’ treatment recommendations
Physician characteristics were relatively unimportant to
treatment recommendations in any of the given scenarios
(data not shown). When compared with no change in ther-
apy, cardiovascular risk factors and the desire to achieve an
even lower LDL-C goal were the most prominent prognos-
tic factors considered to impact physician decision-making,
irrespective of active treatment recommendation or LDL-C
scenario (Figures 1, 2 and 3; Additional file 1). Cardiovas-
cular risk factors and desire to achieve a more aggressive
LDL-C goal were also the factors most likely to be consid-
ered in decision-making by physicians when recommend-
ing more intensive treatment i.e., double atorvastatin dose,
add ezetimibe, or double atorvastatin dose and add ezeti-
mibe (Figures 1, 2 and 3; Additional file 1). Prior response
to statin (whether poor or good), reimbursement status,
LDL-C far from goal, and LDL-C close to goal were also
patient factors that contributed strongly, but variably, to
decision-making. Other prognostic factors included obes-
ity, cost of medication, age, high triglyceride, and gender
(Figures 1, 2 and 3; Additional file 1). Concerns regarding
side effects were considered more often by physicians
when recommending no change in therapy than other
treatments, in particular for the scenarios of LDL-C pre-
sumed far from goal and baseline LDL-C known.
Estimated lipid outcomes (with physician-recommended
treatments) versus randomized controlled trial lipid
outcomes
As expected, patients receiving a relatively intensive treat-
ment regimen in the RCT showed the largest LDL-C
Table 3 Most common treatment recommendations by LDL-C scenario
Recommendation Scenario (% patients) LDL-C observed
BL RCT level
(mg/dL)
1 2 3
LDL-C presumed
near goal
LDL-C presumed far
from goal
LDL-C level known at
pre-randomization
100–105 mg/dL ~ 120 mg/dL
No change in therapy 42.3 6.5 17.5 111.4
Double ATV dose 42.8 52.2 46.5 119.2
Add EZE 8.7 15.6 15.0 123.7
Double ATV dose and
add EZE
2.0 11.6 9.3 129.3
Switch to RSV 1.0 4.3 2.6 124.8
Values shown are mean values.
ATV, atorvastatin; BL, baseline; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; RCT, randomized clinical trial; RSV, rosuvastatin.
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the end of period I), the observed reduction from baseline
in LDL-C in patients randomized to ezetimibe 10 mg +
atorvastatin 10 mg was −21%. This compared with an esti-
mated reduction (based on patients’ pre-randomizationFigure 1 Association of patient factors with physicians’ treatment recomm
factors selected by forward stepwise regression model of physician treatme
RR >1: prognostic factor more likely to be selected by the physician in thei
RR <1: prognostic factor less likely to be selected versus no change in ther
treatment options, with some only selected with very low frequency. To pr
relate only to the four most common treatment choices selected. CI, confiden
RR, relative risk.LDL-C and expected incremental change in LDL-C
6 weeks after initiation of recommended treatment
choice) of only −10% when physicians recommended
doubling of atorvastatin dose to 20 mg (Figure 4a).
Similarly, the number of patients receiving ezetimibeendations relative to observed baseline LDL-C from RCT. Prognostic
nt choice, relative to no change in therapy (n = 268), RR (95% CI).
r treatment choice compared to a choice of no change in therapy;
apy. The questionnaire allowed physicians to choose from many
ovide optimal focus on investigator behavior, the patient factors shown
ce interval; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol;
Figure 2 Association of patient factors with physicians’ treatment recommendations relative to LDL-C presumed near to goal (100–105 mg/dL).
Prognostic factors selected by forward stepwise regression model of physician treatment choice, relative to no change in therapy (n = 648), RR
(95% CI). RR >1: prognostic factor more likely to be selected by the physician in their treatment choice compared to a choice of no change in
therapy; RR <1: prognostic factor less likely to be selected versus no change in therapy. The questionnaire allowed physicians to choose from
many treatment options, with some only selected with very low frequency. To provide optimal focus on investigator behavior, the patient factors
shown relate only to the four most common treatment choices selected. CI, confidence interval; CV, cardiovascular; LDL-C, low-density lipoprotein
cholesterol; RR, relative risk.
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LDL-C <100 mg/dL was greater than the estimated
number of patients achieving the same goal when physi-
cians recommended doubling the atorvastatin dose to
20 mg (59% vs 30%, respectively) (Figure 4b and Additional
file 2).
Notably, the observed reduction in LDL-C for ezeti-
mibe 10 mg + atorvastatin 10 mg (i.e., add ezetimibe) in
the RCT was the same as that estimated when physicians
recommended this treatment (both −24%). In patients
where double atorvastatin dose was recommended, 30%
were estimated to achieve goal, which was lower than the
proportion that were observed to achieve goal during the
RCT (41–59%) (Figure 4). In contrast, when add ezetimibe
was recommended by physicians, the number of patients
estimated to reach LDL-C goal (65%) was greater than
observed during the RCT for patients receiving ezeti-
mibe 10 mg + atorvastatin 10 mg (53%), atorvastatin
20 mg (29%), or rosuvastatin 10 mg (40%). In patientsrecommended to receive double atorvastatin dose and
add ezetimibe, the estimated reduction in LDL-C (26%)
was also higher than observed for the studied treatment
regimens during the RCT (−9 to −15%). Similarly, the
proportion of these patients estimated to achieve LDL-
C <100 mg/dL (57%) was higher than observed in the
RCT (28–36%).
In the original RCT, patients whose LDL-C remained
elevated (≥100 mg/dL) at the end of period I changed to
a more intensive treatment during period II (Figure 5)
[23]. The addition of ezetimibe 10 mg to atorvastatin
20 mg for 6 weeks during period II produced significantly
greater reductions from baseline in LDL-C than doubling
the atorvastatin dose to 40 mg (−16% vs −6%; p < 0.001)
and a significantly greater proportion of patients attained
LDL-C <100 mg/dL (56% vs 34%; p < 0.001) [23]. Simi-
larly, switching from rosuvastatin 10 mg to ezetimibe
10 mg + atorvastatin 20 mg produced significantly greater
reductions in LDL-C from baseline than doubling the
Figure 3 Association of patient factors with physicians’ treatment recommendations relative to LDL-C presumed far from goal (~120 mg/dL).
Prognostic factors selected by forward stepwise regression model of physician treatment choice, relative to no change in therapy (n = 100), RR
(95% CI). RR >1: prognostic factor more likely to be selected by the physician in their treatment choice compared to a choice of no change in
therapy; RR <1: prognostic factor less likely to be selected versus no change in therapy. The questionnaire allowed physicians to choose from
many treatment options, with some only selected with very low frequency. To provide optimal focus on investigator behavior, the patient factors
shown relate only to the four most common treatment choices selected. CI, confidence interval; CV, cardiovascular; LDL-C, low-density lipoprotein
cholesterol; RR, relative risk.
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significantly more patients attained LDL-C <100 mg/dL
(54% vs 36%; p < 0.001).
Discussion
This survey provided a unique opportunity to investigate
real-world factors that most influence physicians’ choice
of lipid-lowering therapy. Physicians’ treatment recom-
mendations were solicited for individual patients who had
received atorvastatin 10 mg during a 5-week pre-treatment
period and were thus eligible for inclusion in a double-
blind RCT designed to assess LDL-C goal attainment rates
with different treatment strategies [23]. As such, the survey
provides real-world insight into the key drivers used by
physicians in the decision-making process for lipid man-
agement in patients with hypercholesterolemia.
A number of key determinants in the physician decision-
making process, primarily cardiovascular risk factors and
the desire to achieve a more aggressive LDL-C goal, were
identified in this survey. Notably, patients randomized to a
relatively intensive treatment regimen tended to have bet-
ter LDL-C-lowering outcomes but in practice physicianstended to be conservative, recommending relatively few
patients to receive such treatments and typically only when
LDL-C was far from goal.
Observational data suggest that, in clinical practice,
more potent LDL-C-lowering efficacy interventions in-
volving the combination of a statin with ezetimibe and/
or statin uptitration are infrequently prescribed to pa-
tients at high cardiovascular risk whose LDL-C remains
elevated on low- to moderate-potency statin monother-
apy [24,25]. In this questionnaire-based study, physicians
were similarly conservative when choosing a regimen for
patients who had not responded adequately to initial treat-
ment with atorvastatin 10 mg, especially if such patients
were close to, but not at, the recommended goal.
Physicians recommended doubling the atorvastatin
dose in approximately 42–50% of patients, regardless of
whether or not the observed baseline LDL-C was known
or presumed to be near or far from goal. Guidelines
generally recommend that the maximum tolerated statin
dose should be used in individuals at high cardiovascular
risk [3,4], although it is recognized that patients may not
achieve adequate LDL-C-lowering on statin therapy alone,
Figure 4 LDL-C outcomes: estimated change from baseline by physician recommendation versus actual observed RCT LDL-C. (a) Percent change
from baseline in LDL-C at Week 6 (b) Percent patients achieving LDL-C <100 mg/dL. Observed (RCT) outcomes at end of period I for randomized
treatment. Estimated outcomes of physician-recommended treatments were based on expected reductions for treatment-naïve patients in
product labels and literature. Estimated outcomes were calculated based on % incremental benefit expected if the recommended treatment were
applied to the observed LDL-C value at the end of the run-in phase for each patient treated with atorvastatin 10 mg; individual estimates were
averaged across all patients where a particular treatment was recommended. The estimated proportion of patients achieving a treatment goal
(<100 or <70 mg/dL) was derived by applying each patient’s estimated LDL-C change associated with the recommended treatment. ATV,
atorvastatin; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled trial; RSV, rosuvastatin.
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Figure 5 Original primary study design. In the original RCT, LDL-C was determined at Week 5 (Period I) to determine eligibility for Period II of
the RCT. At Week 6, patients whose LDL-C levels remained elevated (≥100 and ≤160 mg/dL) had their treatment changed to a more intensive
regimen during Period II. Period II baseline LDL-C was the average of Week 5 and 6 data. Lipids were also assessed at Week 11 and 12. Final
period II values were the average of Week 11 and 12 data. For this analysis, only period I data were used. For further details of the study design,
see Bays et al. 2013 [23]. ATV, atorvastatin; EZE, ezetimibe; RSV, rosuvastatin.
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4–7% when the statin dose is doubled [26,27]. Adverse
events, including myopathy, rhabdomyolysis, and adverse
effects on liver enzymes, can also be increased at relatively
high statin doses [28]. Consequently, combination therapy
with standard statin doses and other lipid-lowering agents
is necessary for individuals whose therapeutic response to
statins is sub-optimal and if the risk-benefit balance is fa-
vorable as recommended in guidelines [4,5,10-12].
We found that when patients’ observed baseline LDL-C
was known to physicians, or when LDL-C was presumed
to be far from goal, physicians recommended add-on ther-
apy with ezetimibe in only 15% of patients. Addition of
ezetimibe 10 mg to ongoing statin therapy has been
shown to reduce LDL-C by an additional 14–22% com-
pared with doubling the statin dose [29-34]. In the RCT
in which this questionnaire-based study was a compo-
nent [23], daily treatment for 6 weeks with ezetimibe
10 mg + atorvastatin 10 mg was associated with reduc-
tion in LDL-C of −20% from baseline for patients not
controlled with atorvastatin 10 mg. This is comparable
with that expected, and significantly better than either
atorvastatin uptitration or a switch to rosuvastatin in
terms of LDL-C change [23]. It is likely that the conser-
vative approach to use of combination therapy seen in
clinical practice has, until recently, reflected a lack of
confidence amongst physicians in the clinical benefit of
LDL-C-lowering by combination therapy due to lack of
evidence showing benefits on CVD-related events in
outcome trials – both fibrates and niacin, for example,have reported negative trial results [35-37]. While the
SHARP (Study of Heart And Renal Protection) trial
demonstrated that combination therapy with statin (sim-
vastatin 20 mg) plus ezetimibe 10 mg was associated with
a significant decrease in major atherosclerotic events,
non-hemorrhagic stroke, and arterial revascularization
procedures compared with placebo in patients with severe
chronic kidney disease, a statin monotherapy arm was not
included in the SHARP study design [38]. The recently
completed IMPROVE-IT trial assessed the cardiovascular
benefit of LDL-C-lowering with ezetimibe 10 mg added to
simvastatin (mainly 40 mg) compared with simvastatin
monotherapy in patients presenting with acute coronary
syndromes. The study investigators reported that the trial
met its primary and secondary composite cardiovascular
efficacy endpoints [39-41].
Clinical inertia or conservatism is an increasingly rec-
ognized factor in poor management of chronic condi-
tions, such as dyslipidemia and type 2 diabetes [19,42].
In certain complex clinical situations, rather than clinical
inertia, it is possible that appropriate inaction may reflect
the need for individualized treatment (i.e. patients with
multiple comorbidities receiving multiple medications)
[19]. There is a need to examine the complex interplay be-
tween provider-, patient-, and system-level barriers that
contribute to clinical inertia [42].
Our survey enabled identification of prognostic fac-
tors considered by physicians during decision-making in
hypercholesterolemia. We found that physician charac-
teristics had no evident impact on physician treatment
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recommendation and was even made for 6.5% of pa-
tients in the hypothetical scenario of LDL-C being far
from goal. Relative to no change in therapy, cardiovascular
risk factors and the desire to achieve a more aggressive
LDL-C goal were the prognostic factors that appeared to
consistently contribute to the physician decision-making
process across all scenarios. Specifically, the desire to
achieve a more aggressive LDL-C goal was the strongest
factor with a consistently high relative risk (RR) across all
scenarios and treatment options. Concerns regarding side
effects also had an impact on decision-making; this factor
was selected more often by the physician when their rec-
ommendation was no change in therapy, compared to the
other treatment recommendations.
Prior response to a statin was a key factor across all
scenarios influencing implementation of combination
therapy with statin and ezetimibe. Consideration of reim-
bursement status generally impacted across all scenarios
and treatment recommendations, being a key determinant
towards use of combination therapy. An overall apparently
counter-intuitive desire to achieve a more aggressive LDL-
C goal and apparent reluctance by physicians to imple-
ment combination therapy may mirror lack of evidence
supporting the use of more potent LDL-C-lowering (com-
bination) therapy in specific patient groups. This observa-
tion is, in fact, consistent with findings in other studies
showing less frequent use of switching to more potent
statin or combination therapy in real-world clinical practice
compared with use of moderate-potency lipid-lowering
therapy; this is very likely attributed to patient non-
compliance/intolerance, health-provider non-adherence to
current guidelines, and/or cost factors [13,43]. The situ-
ation may be countered by recent reports from IMPROVE-
IT [39-41]. Other approaches may include benchmarking,
which has been shown to provide a potential means to
drive quality of care and improve target attainment of
modifiable risk factors in type 2 diabetes [44].
A key strength of this study is that questionnaires were
provided prior to treatment results. The data reflects un-
biased physician perspectives for clinical management of
dyslipidemia. Physicians were more conservative in their
treatment choice than guidelines generally recommend.
Physicians recommended more aggressive treatment reg-
imens if LDL-C was far from the goal, and estimated
lipid outcomes with these recommendations approached
or surpassed those attained with the more aggressive
randomized treatments. Indeed, when compared with ob-
served lipid outcomes, estimated LDL-C control was bet-
ter if physicians were to have used more comprehensive
strategies rather than simply doubling the statin dose. This
is further consistent with the observed LDL-C outcomes
from period II of the RCT where more intensive lipid-
lowering regimens, such as add-on therapy with ezetimibe,produced incremental improvements in LDL-C-lowering
and LDL-C goal attainment in patients who had persist-
ently elevated LDL-C levels following 6 weeks’ of therapy
with more conservative strategies, such as atorvastatin
20 mg or rosuvastatin 10 mg [23].
Several factors may be considered limitations. Differ-
ing health care systems may influence treatment prac-
tices. Through willingness to participate in the trial, it
might be expected the primary care physicians and spe-
cialists in our study sample would have a greater interest
in lipid management than those in broader clinical prac-
tice, and may be more familiar with best-practice guide-
lines. However, this did not seem to have a major influence
on the findings as the original RCT design resulted in upti-
tration and/or switching to a more potent statin in more
than 90% of patients [23], whereas 18% of physicians rec-
ommended no change in therapy, less than half recom-
mended uptitration and relatively few (<3%) endorsed
switching to a more potent statin, even when the baseline
LDL-C was known. We believe that in clinical practice,
where various real-life patient factors (e.g., age, social
environment, comorbid conditions, likelihood of adher-
ence) affect physicians’ prescribing patterns, most phy-
sicians would be even more conservative in their
treatment approach.
Conclusion
This study provides insight into physicians’ perspectives
on the clinical management of hypercholesterolemia and
highlights a gap in guideline implementation. Specific-
ally, physicians adopt a generally conservative approach
towards treating patients to LDL-C targets, tending to
overestimate the magnitude of any effect of doubling
the statin dose. LDL-C levels close to goal may contrib-
ute to physician reluctance to manage patients more ag-
gressively. Improved understanding of the factors that
influence physicians’ treatment recommendations will
help guide better guideline implementation and that
may overall contribute to better lipid management in
clinical practice.
Methods
Study design
This questionnaire-based survey was performed in the
context of a phase III, two-period, multicenter, double-
blind RCT (NCT01154036), published previously [23].
The questionnaire was pre-specified in the study protocol
and, along with the RCT, was approved by the institutional
review boards at each site (Additional file 3). Written in-
formed consent was obtained from all participants.
In brief, high-risk patients with hypercholesterolemia
(either treatment-naïve with LDL-C 166–190 mg/dL,
or on stable lipid-lowering therapy with historic lipid
values within a range that might reasonably meet the
Table 4 Expected reductions in LDL-C with atorvastatin
10 mg and the four most common treatment regimens
from the questionnaire [31,45-49]
Treatment Expected LDL-C
reduction (%)*
Estimated additional
LDL-C reduction for
patients on ATV
10 mg (%)
ATV 10 mg 38 -
ATV 20 mg 44 10
EZE 10 mg + ATV 10 mg 53 24
EZE + ATV 20 mg 54 26
RSV 10 mg 49 18
*Treatment-naïve patients.
ATV, atorvastatin; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol;
RSV, rosuvastatin.
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in period on atorvastatin 10 mg/day (Figure 5). At the end
of the run-in period, patients with LDL-C levels ≥100
and ≤160 mg/dL, and triglyceride levels ≤400 mg/dL,
were randomized to ezetimibe 10 mg plus atorvastatin
10 mg, atorvastatin 20 mg, or rosuvastatin 10 mg daily for
6 weeks (period I of the RCT). During period II of the
RCT, patients whose LDL-C levels remained elevated at
Week 6 changed to a more intensive treatment (Figure 5).
This analysis included data only from Period 1.
Questionnaire
Just prior to randomization into period I of the study
i.e., at the randomization visit, physicians were asked to
complete a 10-item questionnaire for each patient
(Additional file 4). The questionnaire was designed to
survey physicians’ pragmatic therapy recommendations
for three possible scenarios as if the patient were not
enrolled in the RCT and based on the following: (1)
LDL-C presumed near goal (between 100–105 mg/dL),
(2) LDL-C presumed far from goal (~120 mg/dL), and
(3) the observed baseline LDL-C value of each patient
on atorvastatin 10 mg, 1 week prior to randomization.
For each scenario, physicians were asked to select
from a pre-defined list of treatment choices they would
make for each patient (i.e., no change in therapy, double
the atorvastatin dose [to 20 mg], add ezetimibe, switch
to a different statin, add niacin or fibrates, or other).
Multiple choices and write-in choices were also permit-
ted. The questionnaire also asked physicians to specify
which patient factors they would consider in deciding
their real-life treatment choice(s): LDL-C close to the goal;
LDL-C far from goal; desire to achieve more aggressive
goal; cardiovascular risk factors; obesity/metabolic syn-
drome; low high-density lipoprotein cholesterol; high tri-
glyceride; concerns regarding side effects; prior good
response to statin; prior poor response to statin; age; sex;
patient preference; cost of medication to patient; and re-
imbursement status. The questionnaire also collected data
on patient age, gender, and prior history of CVD, as well
as physician characteristics such as type and duration of
clinical practice.
Estimated percent change in LDL-C based on the pa-
tient’s observed pre-randomization (visit 3; 1 week prior
to randomization) LDL-C and the treatment choice rec-
ommended by the investigator was compared to the ob-
served percent change in LDL-C following 6 weeks of
randomized treatment in period I. Outcomes were defined
as the percent change in LDL-C from randomization to
Week 6, and the proportion of patients during this period
who achieved LDL-C <100 mg/dL or LDL-C <70 mg/dL.
The estimated percent change in LDL-C for a recom-
mended treatment choice was calculated from the patient’s
pre-randomization (visit 3) LDL-C and the expectedincremental change in LDL-C 6 weeks after initiation of
the treatment choice recommended by the physician,
based on product labeling information and published
data (Table 4) [31,45-49]. Estimated outcomes i.e., the
proportion of patients achieving LDL-C <100 or <70 mg/
dL, were calculated based on the percent incremental
benefit that would be expected if the recommended treat-
ment were applied to the observed LDL-C value at visit 3
(1 week prior to randomization) for each patient treated
with atorvastatin 10 mg.Statistical analysis
All analyses were performed on the all-patients-as-
treated population that included all patients random-
ized into period I and who received at least one dose of
study drug.
To identify prognostic clinical factors, physician char-
acteristics, and patient factors that influenced physician
treatment choice (as mentioned above), the four most
commonly selected treatment recommendations were
subject to a pre-specified multivariate forward stepwise
regression model. Significant prognostic factors retained
from the forward stepwise regression model (at a signifi-
cance level of 0.15) were analyzed using a univariate
approach to obtain the RR and corresponding 95% con-
fidence interval for each prognostic factor for each of
the most common treatment choices versus the refer-
ence category of no change in therapy. Three separate
analyses were conducted for each of the hypothetical
and real LDL-C scenarios. An RR >1 indicated that the
prognostic factor was more likely to be considered by the
physicians in their treatment choice compared to a choice
of no change in therapy. Conversely, an RR score <1
suggested the prognostic factor was less likely to be a
consideration in selecting a particular treatment, versus
no change in therapy.
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